Associated Papers
Identification of natural product 3, 5-diiodotyrosine as APOBEC3B inhibitor to prevent somatic mutation accumulation and cancer progression.
Chen C et al.
Journal for Immunotherapy of Cancer, 2022
36323433 (PubMed )
Supplement: jitc-2022-005503supp001.pdf
Analysis of De Novo Mutations in Sporadic Cardiomyopathies Emphasizes Their Clinical Relevance and Points to Novel Candidate Genes.
Franaszczyk M et al.
Journal of Clinical Medicine, 2020
Nuclear Magnetic Resonance Structure of the APOBEC3B Catalytic Domain: Structural Basis for Substrate Binding and DNA Deaminase Activity.
Byeon IJ et al.
Biochemistry, 2016
A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3'UTR enhances chromosomal DNA damage.
Caval V et al.
Nature Communications, 2014
APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism.
Stenglein MD et al.
The Journal of Biological Chemistry, 2006
Select a paper to view details